INKT – mink therapeutics, inc. (US:NASDAQ)
Stock Stats
News
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 [Yahoo! Finance]
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 [Yahoo! Finance]
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
Form 3 MiNK Therapeutics, Inc. For: Mar 13 Filed by: Orilall Melissa
Form 10-K MiNK Therapeutics, Inc. For: Dec 31
Form 8-K MiNK Therapeutics, Inc. For: Mar 31
Form 8-K MiNK Therapeutics, Inc. For: Mar 27
Form 3 MiNK Therapeutics, Inc. For: Mar 13 Filed by: Charette Austin
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.